Critical Reviews™ in Eukaryotic Gene Expression

ISSN for PRINT: 1045-4403

For Online Access

Best Paper Award Selection - Editorial Board Site

2005, Volume15

Issue 1

97 pages

DOI: 10.1615/CritRevEukaryotGeneExpr.v15.i1

Issue price - $169.00

Liang Zhang
Department of Biomedical Sciences, College of Medicine, University of Illinois at Chicago, Rockford, IL61107; and Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294

Nasser Said-Al-Naief
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294

Xu Feng
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294

Jay M. McDonald
Department of Pathology, University of Alabama at Birmingham, AL 35294; and Veterans Administration Medical Center, Birmingham, AL 35233

Enhanced osteoclastogenesis is an important pathological feature in several aging-associated bone diseases. Thus, research activities on osteoclastogenesis have been intense during the last ten years. There has been great progress made in this field, however, and in this review, we will focus on current advances in understanding the role of Ca²⁺/calmodulin signaling in osteoclastogenesis. There are two major Ca²⁺/calmodulin signaling pathways emerging as important in osteoclastogenesis. The first is from our recent data, which has established a specific role for calmodulin in osteoclastogenesis and, more specifically, calmodulin-dependent kinase II (CaMKII). The other is that a pathway involving RANK-Ca²⁺-calmodulin—calcineurin—NFAT is critical for osteoclastogenesis. Collectively, these reports highlight the importance of Ca²⁺/calmodulin signaling in osteoclastogenesis, which may present novel targets for the new therapeutic agents to combat bone loss.

DOI: 10.1615/CritRevEukaryotGeneExpr.v15.i1.10 Download article, 1-13 pages

Article price - $35.00

  Next article >>